Rankings
▼
Calendar
PCVX Q4 2025 Earnings — Vaxcyte, Inc. Revenue & Financial Results | Market Cap Arena
PCVX
Vaxcyte, Inc.
$9B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$5M
Operating Income
-$274M
Net Income
-$247M
EPS (Diluted)
$-1.81
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$225M
Free Cash Flow
-$219M
Stock-Based Comp.
$36M
Balance Sheet
Total Assets
$3.0B
Total Liabilities
$360M
Stockholders' Equity
$2.7B
Cash & Equivalents
$174M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$5M
$0
—
Operating Income
-$274M
-$162M
-69.1%
Net Income
-$247M
-$137M
-79.8%
← FY 2025
All Quarters